Compare GIL & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIL | DNTH |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.9B |
| IPO Year | 1999 | 2018 |
| Metric | GIL | DNTH |
|---|---|---|
| Price | $32.99 | $84.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 18 |
| Target Price | $50.88 | ★ $139.25 |
| AVG Volume (30 Days) | ★ 1.9M | 723.8K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | $53.26 | $22.80 |
| Revenue Next Year | $0.39 | N/A |
| P/E Ratio | $23.11 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $31.34 | $35.84 |
| 52 Week High | $73.70 | $117.88 |
| Indicator | GIL | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 33.25 | 44.01 |
| Support Level | $31.34 | $79.54 |
| Resistance Level | $43.16 | $91.36 |
| Average True Range (ATR) | 1.61 | 4.84 |
| MACD | -0.16 | -0.08 |
| Stochastic Oscillator | 17.51 | 19.24 |
Gildan is a vertically integrated designer and manufacturer of basic apparel, including T-shirts, underwear, socks, and hosiery. It is a leader in blank T-shirts, sweatshirts, and other apparel to wholesalers, major clothing brands, and printers (printwear). Gildan also sells branded clothing through retail and direct-to-consumer channels, a business that was greatly enhanced by the Hanesbrands acquisition in 2025. Gildan's labels include Hanes, Bali, Maidenform, Playtex, Gildan, American Apparel, Comfort Colors, and Goldtoe. Gildan produces most of its clothing at factories in Latin America but has been ramping up production at its new facility in Bangladesh. Incorporated in 1984, the Montreal-based company operates internationally but generated 90% of its sales in the US in 2025.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.